Fig. 3From: Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directionsPotential combination therapies according to the immune profiles of hepatocellular carcinoma (HCC). CTLA4: cytotoxic T lymphocyte antigen-4; PD-1: programmed cell death-1; TILs: tumor-infiltrating lymphocytes; TAM: tumor-associated macrophage; TGF-β: Transforming growth factor βBack to article page